The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 801–900 of 999
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity
Opdenakker, G., & Damme, J. V. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.01.004 · Cited by 9
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic
Donahue, R. N., Marté, J. L., Goswami, M., Toney, N. J., Tsai, Y.-T., Gulley, J. L., & Schlom, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002087 · Cited by 9
Dijkstra, J. M., Frenette, A. P., & Dixon, B. (2021) · F1000Research · doi:10.12688/f1000research.51479.1 · Cited by 10
An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19
Monzavi, S. M., Naderi, M., Ahmadbeigi, N., Kajbafzadeh, A. M., & Muhammadnejad, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104398 · Cited by 8
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
Olea, B., Albert, E., Torres, I., Amat, P., Remigia, M. J., Gozalbo‐Rovira, R., Rodríguez‐Díaz, J., Buesa, J., Blasco, M. L., Redón, J., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104943 · Cited by 9
Dispinseri, S., Marzinotto, I., Brigatti, C., Pirillo, M. F., Tolazzi, M., Bazzigaluppi, E., Canitano, A., Borghi, M., Gallinaro, A., Caccia, R., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01190-5 · Cited by 9
Durkee-Shock, J. R., Lazarski, C. A., Jensen-Wachspress, M. A., Zhang, A., Son, A., Kankate, V. V., Field, N. E., Webber, K., Lang, H., Conway, S. R., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.013 · Cited by 9
T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
Chu, C., Schönbrunn, A., Elitok, S., Kern, F., Schnatbaum, K., Wenschuh, H., Klemm, K., von Baehr, V., Krämer, B. K., & Hocher, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.05.025 · Cited by 9
Self-citationWestphal, T., Mäder, M., Karsten, H., Cords, L., Knapp, M., Schulte, S., Hermanussen, L., Peine, S., Ditt, V., Grifoni, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182504 · Cited by 9
Host genetic factors and susceptibility to SARS‐CoV ‐2 infection
Schurr, T. G. (2020) · American Journal of Human Biology · doi:10.1002/ajhb.23497 · Cited by 9
Stefano, G. B., & Kream, R. M. (2020) · Medical Science Monitor · doi:10.12659/msm.929789 · Cited by 8
SARS-CoV-2 escapes CD8 T cell surveillance via mutations in MHC-I restricted epitopesPreprint
Agerer, B., Koblischke, M., Gudipati, V., Smyth, M., Popa, A., Genger, J., Endler, L., Florian, D. M., Mühlgrabner, V., Lercher, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423507 · Cited by 9
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00533-4 · Cited by 8
A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic.
Romão, V. C., Oliveira‐Ramos, F., Cruz-Machado, A. R., Martins, P., Barreira, S. C., Silva-Dinis, J., Galaio, L., Proença, H., Melo‐Cristino, J., Sacadura‐Leite, E., et al. (2020) · PubMed Central · doi:10.3389/fmed.2020.576162 · Cited by 8
Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8
SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
Duan, L., Cui, X., Zhu, K.-L., Lin, Y., Wang, G., Cao, W., & Ma, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111284 · Cited by 8
Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Henze, L., Braun, J., Meyer‐Arndt, L., Jürchott, K., Schlotz, M., Michel, J., Grossegesse, M., Mangold, M., Dingeldey, M., Kruse, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1056525 · Cited by 7
Self-citationClonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
Sheetikov, S. A., Khmelevskaya, A. A., Zornikova, K. V., Zvyagin, I. V., Shomuradova, A. S., Serdyuk, Y. V., Shakirova, N. T., Peshkova, I. O., Titov, A., Romaniuk, D. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369436 · Cited by 8
García‐Torre, A., Bueno‐García, E., López‐Martínez, R., Rioseras, B., Moro‐García, M. A., Alonso, S., Lluna-González, A., Sousa-Fernández, A., Fernández-Gudin, M., Campos-Riopedre, L., et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab206 · Cited by 7
Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination
Lanuti, P., Rossi, C., Cicalini, I., Pierdomenico, L., Damiani, V., Semeraro, D., Verrocchio, S., Boccio, P. D., Evangelista, A., Sarra, A., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081035 · Cited by 8
COVID-19 and Chronic Lymphocytic Leukemia
Chatzikonstantinou, T., Herishanu, Y., Montserrat, E., Ghia, P., Cuneo, A., Foà, R., & Scarfò, L. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000535 · Cited by 9
Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2
Zar, H. J., Nicol, M. P., MacGinty, R., Workman, L., Petersen, W., Johnson, M., & Goldblatt, D. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003325 · Cited by 7
Practical Management of Patients with Atopic Dermatitis on Dupilumab
Papp, K. A., Hong, C.-H., Lansang, M. P., Turchin, I., Adam, D. N., Beecker, J. R., Bissonnette, R., Gooderham, M., Jack, C. S., Joseph, M., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00586-w · Cited by 9
Kongsbak‐Wismann, M., Al-Jaberi, F. A. H., Schmidt, J. D., Ghanizada, M., Hansen, C. B., Lopez, D. V., Woetmann, A., Ødum, N., Bonefeld, C. M., Stryhn, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758154 · Cited by 8
SARS-CoV-2–Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals
Liu, Y., Budylowski, P., Dong, S., Li, Z., Goroshko, S., Leung, L. Y. T., Grunebaum, E., Campisi, P., Propst, E. J., Wolter, N. E., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100606 · Cited by 8
COVID-19 in Africa: Catalyzing change for sustainable development
Karim, S. S. A., Kelemu, S., & Baxter, C. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003869 · Cited by 8
Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
Türkkan, A., Saglik, I., Turan, C. A., Sahin, A., Akalin, H., Ener, B., Kara, A., Celebi, S., Sahin, E., & HACIMUSTAFAOĞLU, M. K. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02716-x · Cited by 8
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
Park, H., Park, M. S., Seok, J. H., You, J., Kim, J., Kim, J., & Park, M. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1598-x · Cited by 8
T helper cell subsets and related target cells in acute COVID-19
Kudryavtsev, I. V., Головкин, А. С., & Тотолян, А. А. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-thc-1882 · Cited by 8
Contact map dependence of a T-cell receptor binding repertoire
Chau, K. N., George, J. T., Onuchic, J. N., Lin, X., & Levine, H. (2022) · Physical review. E · doi:10.1103/physreve.106.014406 · Cited by 8
Bresler, S. C., Menge, T. D., Tejasvi, T., Carty, S. A., & Hristov, A. C. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14371 · Cited by 8
Kinetics of Immune Subsets in COVID-19 Patients Treated with Corticosteroids
Pappas, A., Chaliasou, A.-L., Panagopoulos, A., Dede, K., Daskalopoulou, S., Moniem, E. H. M. A. A., Polydora, E., Grigoriou, E., Psarra, K., Tsirogianni, A., et al. (2022) · Viruses · doi:10.3390/v15010051 · Cited by 8
Ambati, S., Ali, B., Seddon, O., Godkin, A. J., Scurr, M. J., Moore, C., Rowntree, C. J., & Underwood, J. (2023) · International Journal of Hematology · doi:10.1007/s12185-022-03518-2 · Cited by 8
Collora, J. A., Liu, R., Albrecht, K., & Ho, Y. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000655 · Cited by 8
Lin, P., Liang, C.-Y., Yao, B., Chen, H., Pan, C.-F., Wu, L., Lin, Y.-H., Hsu, Y.-S., Liu, Y.-H., Chen, P., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.010 · Cited by 8
A single immunization with cellular vaccine confers dual protection against SARS‐CoV ‐2 and cancer
Shimizu, K., Ueda, S., Kawamura, M., Satoh, M., & Fujii, S. (2022) · Cancer Science · doi:10.1111/cas.15434 · Cited by 7
Schulien, I., Kemming, J. S., Oberhardt, V., Wild, K., Seidel, L. M., Killmer, S., Sagar, Daul, F., Lago, M. S., Decker, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.13.249433 · Cited by 8
Namuniina, A., Muyanja, E., Biribawa, V. M., Okech, B. A., Ssemaganda, A., Price, M. A., Hills, N. K., Nanteza, A., Bagaya, B. S., Weiskopf, D., et al. (2023) · medRxiv · doi:10.1101/2023.01.16.23284626 · Cited by 8
Epidemiology of endemic human coronavirus infection during the COVID-19 pandemic
Kakuya, F., Terao, R., Onoda, H., Okubo, H., Fujiyasu, H., INYAKU, F., Fukuura, A., Arai, T., & Kinebuchi, T. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.11.012 · Cited by 8
Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity
Tu, T. H., Grunbaum, A., Santinon, F., Kazanova, A., Rozza, N., Kremer, R. B., Mihalcioiu, C. L. D., & Rudd, C. E. (2024) · Communications Biology · doi:10.1038/s42003-024-05922-2 · Cited by 7
Manurung, M. D., Sonnet, F., Hoogerwerf, M.-A., Janse, J. J., Kruize, Y. C. M., de Bes-Roeleveld, L., König, M. H., Loukas, A. C., Dewals, B. G., Supali, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50313-0 · Cited by 7
Shimizu, J., Sasaki, T., Ong, G. H., Koketsu, R., Samune, Y., Nakayama, E. E., Nagamoto, T., Yamamoto, Y., Miyazaki, K., & Shioda, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-77969-4 · Cited by 18
Ceraolo, M. G., Leccese, M., Cassotta, A., Triolo, S., Bombaci, M., Coluccio, E. B., Prati, D., Ungaro, R., Abrignani, S., Bandera, A., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202451404 · Cited by 8
Pal, N., Mavi, A. K., Kumar, S., Kumar, U., Joshi, M. D., & Saluja, R. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06894 · Cited by 8
Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients
Anft, M., Blazquez‐Navarro, A., Stervbo, U., Skrzypczyk, S., Witzke, O., Wirth, R., Choi, M., Hugo, C., Reinke, P., Meister, T. L., et al. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01092-0 · Cited by 7
Hu, W., He, M., Wang, X., Sun, Q., & Kuang, M. (2021) · Vaccines · doi:10.3390/vaccines9101093 · Cited by 7
When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak
Taoufik, Y., de Herve, M.-G. D. G., Corgnac, S., Dürrbach, A., & Mami‐Chouaib, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692598 · Cited by 7
Lundgren, A., Leach, S., Axelsson, H., Isakson, P., Nyström, K., Scharf, L., Andersson, B. A., Miron, N., Marklund, E., Andersson, L., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad044 · Cited by 7
Ke, Y., Zhang, E., Guo, J., Zhang, X., Wang, L., Chen, D., Fang, X., Zhu, J., Li, F., Sun, T., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.023 · Cited by 7
Nonconserved epitopes dominate reverse preexisting T cell immunity in COVID-19 convalescents
Wang, X., Zhang, J., Liu, M., Guo, Y., Guo, P., Yang, X., Shang, B., Li, M., Tian, J., Zhang, T., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01876-3 · Cited by 7
Poteryaev, D. A., Авгатович, Х. Р., Efimov, G. A., & Shuster, А. М. (2020) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2020-20-3-146-158 · Cited by 7
Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology
Dubey, A., Dahiya, S., Rouse, B. T., & Sehrawat, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581076 · Cited by 6
Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients
Nailescu, C., Khalid, M., Wilson, A. C., Amanat, F., Arregui, S., Canas, J., Hooks, J., Krammer, F., Schwaderer, A. L., & Hains, D. S. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.601327 · Cited by 8
War der Coronavirus-Lockdown notwendig?
Richter, D. (2021) · transcript Verlag eBooks · doi:10.14361/9783839455456 · Cited by 7
Castro, A., Öztürk, K., Zanetti, M., & Carter, H. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246731 · Cited by 8
The conundrum of current anti-SARS-CoV-2 vaccines
Federico, M. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.03.001 · Cited by 7
Wang, J., Guo, C., Cai, L., Liao, C., Yi, H., Li, Q., Hu, H., Deng, Q., Lu, Y., Guo, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772511 · Cited by 7
Bakkari, M. A., Moni, S. S., Sultan, M. H., & Madkhali, O. A. A. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220106110014 · Cited by 8
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
Gao, X., Fan, L., Zheng, B., Li, H., Wang, J., Zhang, L., Li, J., & Zhu, F. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2055373 · Cited by 8
Österdahl, M. F., Christakou, E., Hart, D. J., Harris, F., Shahrabi, Y., Pollock, E., Wadud, M., Spector, T. D., Brown, M. A., Seow, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28016 · Cited by 5
A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccine
Sakamoto, A., Osawa, H., Hashimoto, H., Mizuno, T., Hasyim, A. A., Abe, Y.-I., Okahashi, Y., Ogawa, R., Iyori, M., Shida, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122580 · Cited by 7
Lani, R., Senin, N. A., AbuBakar, S., & Hassandarvish, P. (2022) · Vaccines · doi:10.3390/vaccines10101606 · Cited by 6
Li, J., Reinke, S., Yu, S., Schollmeyer, L., Liu, Y.-C., Wang, Z., Hardt, S., Hipfl, C., Hoffmann, U., Frischbutter, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1004656 · Cited by 7
Distorted TCR repertoires define multisystem inflammatory syndrome in children
Malik, A., Tóth, E. N., Teng, M. S., Hurst, J. M., Watt, E., Wise, L., Kent, N., Bartram, J. L., Grandjean, L., Dominguez‐Villar, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274289 · Cited by 8
Immunology of SARS-CoV-2 infection and vaccination
Lin, B., Cheng, L., Zhang, J., Yang, M. X., Zhang, Y., Liu, J., & Qin, X. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117390 · Cited by 8
Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H., Aviszus, K., Zelarney, P. T., Liao, S., Gerber, A. N., Make, B. J., Wechsler, M. E., Marrack, P., & Reinhardt, R. L. (2023) · ERJ Open Research · doi:10.1183/23120541.00400-2023 · Cited by 7
Approaches to evaluate the specific immune responses to SARS-CoV-2
López-Gomez, A., Pelaez-Prestel, H. F., & Juárez, I. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.033 · Cited by 7
Stern, D., Meyer, T. C., Treindl, F., Mages, H. W., Krüger, M., Skiba, M., Krüger, J. P., Zobel, C., Schreiner, M., Grossegesse, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48581-9 · Cited by 8
Self-citationCOVID-19. El manejo ambulatorio durante la transmisión comunitaria intensa
Huaroto, C. T., Espinoza, M., & Ticona, E. (2020) · Anales de la Facultad de Medicina · doi:10.15381/anales.v81i2.18406 · Cited by 7
Heinz, F. X., & Stiasny, K. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01763-1 · Cited by 8
Phenotyping of Adaptive Immune Responses in Inflammatory Diseases
Humrich, J. Y., Bernardes, J. P., Ludwig, R. J., Klatzmann, D., & Scheffold, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604464 · Cited by 7
Boosted immunity to the common cold might protect children from COVID-19
Lavinder, J. J., & Ippolito, G. C. (2021) · Nature Immunology · doi:10.1038/s41590-021-01094-x · Cited by 7
Georgakilas, G. K., Galanopoulos, A. P., Tsinaris, Z., Kyritsi, M. A., Mouchtouri, V. Α., Speletas, M. G., & Hadjichristodoulou, C. S. (2022) · Biology · doi:10.3390/biology11101531 · Cited by 5
Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma
Hindilerden, İ. Y., Hindilerden, F., Mastanzade, M. G., Tiryaki, T. O., Tasan-Yenigun, S., Bilen, Y., Aksöz, S., Çağatay, A. A., & Nalçacı, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.601709 · Cited by 7
Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Garbán, H., Liu, P., Rice, A., Taft, J. D., Patel, R. S., et al. (2020) · medRxiv · doi:10.1101/2020.11.04.20225417 · Cited by 7
Ashokkumar, C., Rohan, V., Kroemer, A., Rao, S., Mazariegos, G. V., Higgs, B. W., Nadig, S. N., Almeda, J. L., Dhani, H., Khan, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442371 · Cited by 7
Halvorson, T., Ivison, S. M., Huang, Q., Ladua, G. K., Yotis, D. M., Mannar, D., Subramaniam, S., Ferreira, V. H., Kumar, D., Belga, S., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004873 · Cited by 6
B cell intrinsic and extrinsic factors impacting memory recall responses to SRBC challenge
Valeri, V., Sochon, A., Ye, C., Mao, X., Lecoeuche, D., Fillatreau, S., Weill, J., Reynaud, C., & Hao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873886 · Cited by 8
Sannier, G., Nicolas, A., Dubé, M., Marchitto, L., Nayrac, M., Tastet, O., Chatterjee, D., Tauzin, A., Lima-Barbosa, R., Laporte, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100955 · Cited by 6
Galeota, E., Bevilacqua, V., Gobbini, A., Gruarin, P., Bombaci, M., Pesce, E., Favalli, A., Lombardi, A., Vincenti, F., Ongaro, J., et al. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110164 · Cited by 6
Liu, S., Wang, B., Chen, T., Wang, H., Liu, J., Zhao, X., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374541 · Cited by 6
Cossu, C., Franceschi, V., Lorenzo, A. D., Bolli, E., Minesso, S., Cotti, C., Conti, L., & Donofrío, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111509 · Cited by 7
Bozkus, C. C., Brown, M., Velazquez, L. G., Thomas, M., Wilson, E. A., O’Donnell, T. J., Kaminska, A., Ruchnewitz, D., Geertz, D., Bykov, Y., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113044 · Cited by 9
Viral Infections and Nutrition: Influenza Virus as a Case Study
Green, W. D., Karlsson, E. A., & Beck, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-56913-6_5 · Cited by 6
Müller, T. M., Becker, E. M., Wiendl, M., Schulze, L. L., Voskens, C., Völkl, S., Kremer, A. E., Neurath, M. F., & Zundler, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639329 · Cited by 10
Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning
Park, J. J.-Y., & Chen, S. (2021) · Patterns · doi:10.1016/j.patter.2021.100407 · Cited by 6
Mathew, S., Fakhroo, A. D., Smatti, M., Thani, A. A. A., & Yassine, H. M. (2022) · Immunogenetics · doi:10.1007/s00251-021-01250-5 · Cited by 6
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He, X., & Zeng, X. X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s347297 · Cited by 7
Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
Taira, N., Toguchi, S., Miyagi, M., Mori, T., Tomori, H., Oshiro, K., Tamai, O., Kina, M., Miyagi, M., Tamaki, K., et al. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.12.001 · Cited by 7
Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients
Cheng, M., Liu, H., Chao Hui, Z. H. O. U., Li, R.-T., Zheng, J., Qin, Y., Yang, N., Zhang, Y., Huang, J., Zhu, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911859 · Cited by 6
Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810679 · Cited by 6
Liu, Z., Meng, M., Ding, S., Zhou, X., Feng, K., Huang, T., & Cai, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1007295 · Cited by 6
A survey of mechanisms underlying current and potential COVID‐19 vaccines
Hebel, C., & Thomsen, A. R. (2022) · Apmis · doi:10.1111/apm.13284 · Cited by 6
The risk of COVID-19 can be predicted by a nomogram based on m6A-related genes
Lu, L., Li, Y., Ao, X., Huang, J., Liu, B., Wu, L., & Li, D. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105389 · Cited by 6
Schnizer, C., Andreas, N., Vivas, W., Kamradt, T., Baier, M., Kiehntopf, M., Glöckner, S., Scherag, A., Löffler, B., Kolanos, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1095129 · Cited by 6
Somogyi, E., Kremlitzka, M., Csiszovszki, Z., Molnár, L., Lőrincz, O., Tóth, J., de Waal, L., Pattijn, S., Reineking, W., Beineke, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111629 · Cited by 5
Evolution of SARS-CoV-2-specific CD4+ T cell epitopes
Brand, M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01295-8 · Cited by 7
Lesteberg, K. E., Araya, P., Waugh, K. A., Chauhan, L., Espinosa, J. M., & Beckham, J. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113932 · Cited by 7
Liontos, A., Asimakopoulos, A., Markopoulos, G. S., Biros, D., Athanasiou, L., Tsourlos, S., Dova, L., Rapti, I.-C., Tsiakas, I., Ntzani, E., et al. (2023) · Pathogens · doi:10.3390/pathogens12030414 · Cited by 7
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
